FOLD Stock Overview
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases.
Amicus Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$12.32|
|52 Week High||US$12.76|
|52 Week Low||US$5.91|
|1 Month Change||13.55%|
|3 Month Change||64.71%|
|1 Year Change||17.56%|
|3 Year Change||18.80%|
|5 Year Change||-1.52%|
|Change since IPO||-14.62%|
Recent News & Updates
Amicus Therapeutics: AT-GAA Approval Delayed, I Will Continue Holding
Amicus Therapeutics' AT-GAA approval in Pompe Disease has been pushed back by 3 months. However, the stock seems buoyant enough. I will continue holding, taking profits where I can. In my previous coverage in May, I wrote the following desultory text: Amicus Therapeutics, Inc. (FOLD) stock is not able to get to its proper potential despite the company's excellence in running its business. Every time I revisit the company, I am astounded by the compelling thesis, the value-market mismatch, and the ensuing opportunity - and yet the stock fails to deliver. I am happy to report that the stock is up 50% since then, despite the FDA extending the review period "by 90 days for the Biologics License Application (BLA) for cipaglucosidase alfa and the New Drug Application (NDA) for miglustat, the two components of AT-GAA." The AT-GAA BLA is fraught with risk because the trial backing the BLA actually failed to meet the primary endpoint. However, here's what I said before about the PROPEL trial: …although PROPEL missed statistical significance in the combined population of patients for motor function, it achieved stat sig for lung function or FVC, which is the more critical symptom… The funny thing about both the COMET and PROPEL trials is that COMET's primary endpoint was FVC, and 6MWT was its secondary endpoint; in PROPEL, it was the other way round. 6MWT was the primary, and FVC was the secondary endpoint. The funny thing, as I was saying, is that COMET missed the FVC primary endpoint but did better with 6MWT; and PROPEL missed the 6MWT primary endpoint but did better with FVC. Now, Sanofi got an approval from the COMET trial, although it failed its primary endpoint. So I expect AT-GAA to be approved as well. More importantly, COMET failed FVC but got approval on secondary endpoint 6MWT. However, as I noted before, FVC is the more important cause of mortality in Pompe patients. Here, PROPEL met stat sig in FVC, despite failing in 6MWT, its primary endpoint. Thus, its chances of approval seem more than Sanofi's Nexviazyme. So why was the PDUFA delayed by 3 months? According to the press brief, they released on May 10: The FDA extended the PDUFA dates to allow additional time to review information submitted by the Company as part of its ongoing reviews. The extension of the review timeline was not related to requests for any additional clinical data. The Company also expects that the additional time will allow for the completion of the pre-license approval inspections necessary at the WuXi Biologics manufacturing site in China.
Amicus Therapeutics Q2 2022 Earnings Preview
Amicus Therapeutics (NASDAQ:FOLD) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is -$0.22 (-15.8% Y/Y) and the consensus Revenue Estimate is $85.88M (+11.0% Y/Y). Over the last 1 year, FOLD has beaten EPS estimates 50% of the time and has beaten revenue estimates 100% of the time. Over the last 3 months, EPS estimates have seen 0 upward revisions and 3 downward. Revenue estimates have seen 1 upward revision and 8 downward.
|FOLD||US Biotechs||US Market|
Return vs Industry: FOLD exceeded the US Biotechs industry which returned -21.7% over the past year.
Return vs Market: FOLD exceeded the US Market which returned -10.2% over the past year.
|FOLD Average Weekly Movement||8.5%|
|Biotechs Industry Average Movement||12.6%|
|Market Average Movement||7.7%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: FOLD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: FOLD's weekly volatility (8%) has been stable over the past year.
About the Company
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development.
Amicus Therapeutics Fundamentals Summary
|FOLD fundamental statistics|
Is FOLD overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|FOLD income statement (TTM)|
|Cost of Revenue||US$35.33m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.00|
|Net Profit Margin||-87.50%|
How did FOLD perform over the long term?See historical performance and comparison
Is FOLD undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 5/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for FOLD?
Other financial metrics that can be useful for relative valuation.
|What is FOLD's n/a Ratio?|
Price to Sales Ratio vs Peers
How does FOLD's PS Ratio compare to its peers?
|FOLD PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
BPMC Blueprint Medicines
DNLI Denali Therapeutics
FOLD Amicus Therapeutics
Price-To-Sales vs Peers: FOLD is good value based on its Price-To-Sales Ratio (10.8x) compared to the peer average (20.4x).
Price to Earnings Ratio vs Industry
How does FOLD's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: FOLD is good value based on its Price-To-Sales Ratio (10.8x) compared to the US Biotechs industry average (17.2x)
Price to Sales Ratio vs Fair Ratio
What is FOLD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||10.8x|
|Fair PS Ratio||11.6x|
Price-To-Sales vs Fair Ratio: FOLD is good value based on its Price-To-Sales Ratio (10.8x) compared to the estimated Fair Price-To-Sales Ratio (11.6x).
Share Price vs Fair Value
What is the Fair Price of FOLD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: FOLD ($12.32) is trading below our estimate of fair value ($50.95)
Significantly Below Fair Value: FOLD is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
How is Amicus Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?
Future Growth Score6/6
Future Growth Score 6/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FOLD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: FOLD is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: FOLD is expected to become profitable in the next 3 years.
Revenue vs Market: FOLD's revenue (25.4% per year) is forecast to grow faster than the US market (7.9% per year).
High Growth Revenue: FOLD's revenue (25.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: FOLD's Return on Equity is forecast to be high in 3 years time (25.6%)
Discover growth companies
How has Amicus Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: FOLD is currently unprofitable.
Growing Profit Margin: FOLD is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: FOLD is unprofitable, but has reduced losses over the past 5 years at a rate of 2.6% per year.
Accelerating Growth: Unable to compare FOLD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FOLD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).
Return on Equity
High ROE: FOLD has a negative Return on Equity (-162.02%), as it is currently unprofitable.
Discover strong past performing companies
How is Amicus Therapeutics's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: FOLD's short term assets ($497.6M) exceed its short term liabilities ($164.6M).
Long Term Liabilities: FOLD's short term assets ($497.6M) exceed its long term liabilities ($462.5M).
Debt to Equity History and Analysis
Debt Level: FOLD's net debt to equity ratio (2.2%) is considered satisfactory.
Reducing Debt: FOLD's debt to equity ratio has increased from 59% to 225.3% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: FOLD has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if FOLD has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
What is Amicus Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate FOLD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate FOLD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if FOLD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if FOLD's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as FOLD has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Brad Campbell (46 yo)
Mr. Bradley L. Campbell, also known as Brad, MBA, serves as Director of Gennao Bio, Inc. since March 2022. He serves as Director of Alliance for Regenerative Medicine. He served as Chief Operating Officer...
CEO Compensation Analysis
Compensation vs Market: Brad's total compensation ($USD4.91M) is about average for companies of similar size in the US market ($USD6.53M).
Compensation vs Earnings: Brad's compensation has increased whilst the company is unprofitable.
Experienced Management: FOLD's management team is considered experienced (4.4 years average tenure).
Experienced Board: FOLD's board of directors are considered experienced (5.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.2%.
Amicus Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: Amicus Therapeutics, Inc.
- Ticker: FOLD
- Exchange: NasdaqGM
- Founded: 2002
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$3.456b
- Shares outstanding: 280.50m
- Website: https://amicusrx.com
Number of Employees
- Amicus Therapeutics, Inc.
- 3675 Market Street
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/14 00:00|
|End of Day Share Price||2022/08/12 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.